Keyphrases
5-year Survival
8%
BCL6
8%
Cellular Processes
8%
COL1A2
8%
COL5A1
8%
Common Genes
8%
Cyclophosphamide
25%
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Doxorubicin
25%
Extracellular Matrix
8%
Gene Association
8%
Gene Expression
16%
Germinal Center
8%
Hypoxia Response
8%
Hypoxia-inducible Factor
16%
Hypoxia-inducible factor-1α (HIF-1α)
100%
International Prognostic Index
8%
Lymphoma
8%
Multivariate Analysis
8%
Non-germinal Centre
8%
Oncovin
25%
Overall Survival
16%
Patient Outcomes
8%
PLOD2
8%
Prednisone
25%
Prognostic Factors
8%
Prognostic Significance
8%
Progression-free Survival
25%
Protein Expression
16%
Rituximab
8%
Rituximab-CHOP
100%
Significant Predictors
8%
Survival Disparities
8%
Tissue Microarray
8%
Medicine and Dentistry
Biological Marker
8%
CHOP
100%
Cyclophosphamide
25%
Diffuse Large B-Cell Lymphoma
100%
Doxorubicin
25%
Extracellular Matrix
8%
Gene Expression
8%
Germinal Center
16%
Hypoxia
8%
Hypoxia Inducible Factor
16%
Hypoxia Inducible Factor 1
100%
International Prognostic Index
8%
Multivariate Analysis
8%
Overall Survival
25%
Prednisone
25%
Prognostic Factor
8%
Progression Free Survival
25%
Protein Expression
16%
Rituximab
100%
Tissue Microarray
8%
Vincristine Sulfate
25%
Neuroscience
B Cell
100%
BCL6
8%
CHOP
100%
Cyclophosphamide
25%
Doxorubicin
25%
Extracellular Matrix
8%
Gene Expression
8%
Germinal Center
16%
Hypoxia Inducible Factor 1
100%
Hypoxia-Inducible Factors
16%
Microarrays
8%
Prednisone
25%
Protein Expression
16%
Rituximab
100%
Vincristine Sulfate
25%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
BCL6
8%
COL1A2
8%
Cyclophosphamide
25%
Doxorubicin
25%
Gene Expression
8%
Hypoxia Inducible Factor 1
100%
Hypoxia-Inducible Factors
16%
Multivariate Analysis
8%
Overall Survival
25%
Prednisone
25%
Progression Free Survival
25%
Protein Expression
16%
Rituximab
100%
Tissue Microarray
8%
Immunology and Microbiology
B Cell
100%
BCL6
8%
Cyclophosphamide
25%
Extracellular Matrix
8%
Gene Expression
8%
Germinal Center
16%
Hypoxia Inducible Factor
16%
Hypoxia Inducible Factor 1
100%
Overall Survival
25%
Prednisone
25%
Progression Free Survival
25%
Protein Expression
16%
Rituximab
100%